Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Astellas Pharma News

    9,082 € +2,85% +0,252 €
    14:17:29 Uhr Tradegate aktualisieren | Orderbuch | Mehr Kurse »
    WKN: 856273
    ISIN: JP3942400007
    US-Symbol: ALPMF
    Typ: Aktie

    Astellas Pharma News

    02.05.23 - Der Aktionär
    Übernahme‑Kracher: Astellas Pharma schlägt zu
    10.06.22 - DGAP
    Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis
    Hardman & Co Research Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis 10-Jun-2022 / 01:00 GMT/BST
    02.06.21 - Börse Online
    Morphosys schluckt US-Krebsspezialisten - Aktie bricht ein
    Das Biotechunternehmen Morphosys greift für bis zu 1,7 Milliarden Dollar nach dem US-​Krebsspezialisten Constellation Pharmaceuticals. Morphosys bietet 34 Dollar je ...
    13.08.19 - DGAP
    Ludwig Beck am Rathauseck-Textilhaus Feldmeier AG: Veränderungen im Vorstand der LUDWIG BECK AG
    DGAP-News: Ludwig Beck am Rathauseck-​Textilhaus Feldmeier AG / Schlagwort(e): Personalie/Personalie Ludwig Beck am Rathauseck-​Textilhaus Feldmeier AG: Veränderungen ...
    15.09.17 - Handelsblatt
    Anleger unbeeindruckt von Nordkoreas Raketentest
    Nordkorea hat erneut einen Raketentest vollzogen, das Geschoss soll sogar über Japan hinweggeflogen sein. Die Investoren an den asiatischen Märkten lässt das aber kalt. Im ...
    18.05.17 - ARIVA.DE Redaktion
    Die Aktie von Astellas Pharma läuft schlechter: Große Kurs­verluste!
    Keinen Grund zur Freude haben Anleger, die in die Astellas Pharma-​Aktie investiert haben: Der Kurs der Aktie sackt kräftig ab.
    17.05.17 - ARIVA.DE Redaktion
    Astellas Pharma-Aktie leicht im Plus
    Im Wertpapierhandel notiert der Anteilsschein von Astellas Pharma aktuell etwas fester. Der jüngste Kurs betrug 11,71 Euro.
    23.04.17 - PR Newswire
    Use of Extended-Pulsed Regimen with DIFICLIR[TM] (fidaxomicin) is More Effective Than Standard vancomycin in Achieving Sustained Cure of Clostridium difficile Infection (CDI) and Preventing Recurrence
    Use of Extended-​Pulsed Regimen with DIFICLIR[TM] (fidaxomicin) is More Effective Than Standard vancomycin in Achieving Sustained Cure of Clostridium difficile Infection (CDI) ...
    20.04.17 - PR Newswire
    New Study Reveals the Impact of Clostridium difficile Infection (CDI) on the Health Service is Equivalent to an Additional 10,670 Bed Days a Year
    New Study Reveals the Impact of Clostridium difficile Infection (CDI) on the Health Service is Equivalent to an Additional 10,670 Bed Days a Year PR Newswire
    12.12.16 - PR Newswire
    Astellas Announces Transfer of Qutenza™ to Grünenthal
    Astellas Announces Transfer of Qutenza™ to Grünenthal PR Newswire
    28.10.16 - PR Newswire
    Astellas to Acquire Ganymed Pharmaceuticals
    Astellas to Acquire Ganymed Pharmaceuticals PR Newswire
    14.10.16 - PR Newswire
    World Anti-Doping Agency and Astellas Announce Global Initiative to Prevent Misuse and Abuse of Medicines for Doping in Sports
    World Anti-​Doping Agency and Astellas Announce Global Initiative to Prevent Misuse and Abuse of Medicines for Doping in Sports PR Newswire
    14.10.16 - PR Newswire
    World Anti-Doping Agency and Astellas Announce Global Initiative to Prevent Misuse and Abuse of Medicines for Doping in Sports
    World Anti-​Doping Agency and Astellas Announce Global Initiative to Prevent Misuse and Abuse of Medicines for Doping in Sports PR Newswire
    11.04.16 - PR Newswire
    International Consensus Report Highlights Need for Improved Management of Clostridium difficile Infection (CDI) in Inflammatory Bowel Disease (IBD) Patients
    International Consensus Report Highlights Need for Improved Management of Clostridium difficile Infection (CDI) in Inflammatory Bowel Disease (IBD) Patients PR Newswire
    04.03.16 - PR Newswire
    Astellas Pharma Europe Ltd. Announces New President of EMEA Operations
    Astellas Pharma Europe Ltd. Announces New President of EMEA Operations PR Newswire
    04.03.16 - ots
    Astellas Pharma Europe Ltd. Announces New President of EMEA ...
    Astellas Pharma Europe Ltd. Announces New President of EMEA Operations Chertsey, England (ots/PRNewswire) - Astellas Pharma Europe Ltd., a subsidiary of Astellas Pharma ...
    02.12.15 - ots
    Biovista Inc. gibt Zusammenarbeit mit Astellas Pharma zwecks ...
    Biovista Inc. gibt Zusammenarbeit mit Astellas Pharma zwecks Umpositionierung von Arzneimitteln bekannt Charlottesville, Virginia (ots/PRNewswire) - Biovista gab heute den ...
    10.11.15 - PR Newswire
    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Ocata Therapeutics, Inc. of Commencement of an Investigation In Connection With the Fairness of the Sale of the Company to Astella
    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Ocata Therapeutics, Inc. of Commencement of an Investigation In Connection With the Fairness of the Sale ...
    18.09.15 - PR Newswire
    Astellas Granted Label Extension for QUTENZA[TM] (capsaicin 8% patch) to Include Treatment of Diabetic Patients With Peripheral Neuropathic Pain (PNP)
    Astellas Granted Label Extension for QUTENZA[TM] (capsaicin 8% patch) to Include Treatment of Diabetic Patients With Peripheral Neuropathic Pain (PNP) PR Newswire
    16.09.15 - PR Newswire
    Astellas Pharma EMEA beruft Eugene Van Rensburg zum Chief Financial Officer
    Astellas Pharma EMEA beruft Eugene Van Rensburg zum Chief Financial Officer PR Newswire

    Newssuche

    Videos

    newspaper
    09:30 Uhr +49,59%
    Technical Trading: S&P 500 Short Chance
    S&P 500 Short Typ: Turbo Open End WKN: NG8FUZ Hebel: 31 Laufzeit: OpenEnd Einstieg: Market ... Mehr »